Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) gapped up before the market opened on Monday. The stock had previously closed at $13.38, but opened at $14.20. Alpha Tau Medical shares last traded at $12.4850, with a volume of 562,008 shares traded.
Analysts Set New Price Targets
DRTS has been the subject of several research analyst reports. Barclays boosted their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, September 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Alpha Tau Medical in a report on Tuesday, October 20th. Benchmark reaffirmed a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Thursday, October 15th. Finally, Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a report on Monday, November 9th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alpha Tau Medical presently has an average rating of "Moderate Buy" and a consensus target price of $18.20.
Check Out Our Latest Stock Report on Alpha Tau Medical
Alpha Tau Medical Stock Performance
The stock's 50-day moving average is $14.06 and its 200-day moving average is $10.91. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.68 and a beta of 1.28. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15.
Insider Activity
In other news, CFO Raphi Levy sold 2,871 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,352,700. This represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company's stock.
Hedge Funds Weigh In On Alpha Tau Medical
Institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the first quarter valued at about $286,000. Principal Financial Group Inc. acquired a new position in shares of Alpha Tau Medical in the first quarter valued at approximately $132,000. Finally, Everhart Financial Group Inc. acquired a new position in shares of Alpha Tau Medical in the second quarter valued at approximately $126,000. Institutional investors and hedge funds own 2.65% of the company's stock.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.